Expertise in
31
conditions

Dr. Steven Ades

Oncology
Office
89 Beaumont Ave, 
Burlington, VT 
Accepting New Patients
Offers Telehealth
Expertise in
31
conditions
Office
89 Beaumont Ave, 
Burlington, VT 

Overview

Steven Ades is an Oncologist practicing medicine in Burlington, Vermont.

Dr. Ades is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Prostate Cancer, Penile Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 14 clinical trials. Dr. Ades is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in VT

Hospital Affiliations

Porter Hospital Inc
Univ. Of Vermont - Fletcher Allen Health Care
Copley Hospital
The University Of Vermont Health Network - Champl
Central Vermont Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Office
89 Beaumont Ave, Burlington, VT 05405
Other Locations
University of Vermont Medical Center
111 Colchester Ave, Burlington, VT 05401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
Non-Operative Management and Early Response Assessment in Rectal Cancer
Non-Operative Management and Early Response Assessment in Rectal Cancer
Enrollment Status: Completed
Publish Date: May 01, 2026
Intervention Type: Drug, Radiation
Study Phase: Not Applicable
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

35 Total Publications

Impact of Venous Thrombosis Prevention in Ambulatory Oncology: Importance of Guideline Adherence.
Impact of Venous Thrombosis Prevention in Ambulatory Oncology: Importance of Guideline Adherence.
Journal: JCO oncology practice
Published: April 06, 2026
Similar Doctors
Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required

University Of Vermont Medical Center

111 Colchester Ave, 
Burlington, VT 
 (0.1 miles away)
802-847-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Kaufman is an Oncologist practicing medicine in Burlington, Vermont. Dr. Kaufman is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Kaufman is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Fletcher Allen Health Care Inc

1 S Prospect St, 
Burlington, VT 
 (0.3 miles away)
802-847-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Farrah Khan is an Oncologist practicing medicine in Burlington, Vermont. Dr. Khan is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Khan is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

University Of Vermont Medical Center

111 Colchester Ave, 
Burlington, VT 
 (0.1 miles away)
802-847-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Greenblatt is an Oncologist practicing medicine in Burlington, Vermont. Dr. Greenblatt is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, Salpingo-Oophorectomy, and Bone Marrow Aspiration. Dr. Greenblatt is currently accepting new patients.

Frequently Asked Questions about Dr. Steven Ades

How do I make an appointment with Dr. Steven Ades?

You can book an appointment with Dr. Steven Ades by calling their office at 802-847-5487. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Steven Ades a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Steven Ades is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Steven Ades specialize in?

While Dr. Steven Ades is a Oncology, they have specific expertise in Colorectal Cancer, Familial Prostate Cancer, and Penile Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Steven Ades participate in research or clinical trials?

Yes. Dr. Steven Ades has published 35 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Steven Ades's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Steven Ades accept my insurance?

Dr. Steven Ades accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 802-847-5487 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ades's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile